Ç׾ϸ鿪¹Ú»ç(Project Leader)ºÎÀå±ÞÀ» ¸ð½Ê´Ï´Ù.
Çѱ¹ÃÖÃÊ Ç×üġ·áÁ¦ °³¹ß°æÇèÀ» ¹ÙÅÁÀ¸·Î ¼¼°èÀû ¼öÁØÀÇ Ç׾ϸ鿪(Immuno-Oncology)ºÐ¾ßÀÇ
Ç×üġ·áÁ¦ ½Å¾à°úÁ¦¸¦ ¿î¿µ ¹× °ü¸®ÇÒ Senior Scientist¸¦ ¸ð½Ê´Ï´Ù.
ÇзÂ.Àü°ø : ¹Ú»ç/¸é¿ªÇÐ, Ç׾ϸ鿪ÇÐ ºÐ¾ß
¸ðÁýºÎ¹® : Ç׾ϸ鿪 Ç×ü½Å¾à °³¹ß
°æ·Â : Á¦¾à¾÷°è ÀǾàǰ Early Development ´Ü°è 3³âÀÌ»ó
[¾÷¹«] ¸é¿ªÇÐ/Ç׾ϸ鿪 Áö½Ä°ú °æÇèÀ» Ȱ¿ëÇÑ Ç׾ϸ鿪 Ç×üġ·áÁ¦ °úÁ¦ °ü¸®
1. Ç׾ϸ鿪 Ÿ°Ù¿¡ ´ëÇÑ ¸é¿ªÇÐÀû Ä¡·á°¡¼³(Clinical Hypothesis) ¼¼¿ì±â
2. Ä¡·á°¡¼³ ÀÔÁõÇÒ ¸é¿ªÇÐÀû ¿¬±¸ Design - È¿´ÉÆò°¡¹ý °³¹ß ¹× È¿´ÉÆò°¡ °ü¸®
• In vitro: Cytokine & Immune responses
• In vivo: Tumor xenografts or Immune profiling in tumor
• Ex vivo: TILs or ȯÀÚ »ùÇÃÀ» ÀÌ¿ëÇÑ ¸é¿ª È¿´É Æò°¡
3. ½Å±Ô ¹Ú»ç±Þ scientistµé°ú ÇÔ²² °úÁ¦ ¿î¿µ ÁÖµµ
[°æ·Â] Ç×ü°ü·Ã ´Ü¹éÁúÄ¡·áÁ¦ °³¹ß »ê¾÷°è °æÇè (3³â ÀÌ»ó)
Early Discovery (Hit/Lead to Drug candidate) ¹°Áú¹ß±¼ °æÇè
Global big pharma °æ·Â (¿ì´ë)
Open innovation °æÇè (¿ì´ë)
4. ¼·ùÁ¢¼öE-mail : ******@*******.***
´ã´ç : HRKoreaÃÖ°æ¼÷ºÎ»çÀå
Tel : 02-3450-1263